Arshad A Pandith1, Iqbal Qasim1, Shahid M Baba2, Aabid Koul1, Wani Zahoor1, Dil Afroze3, Adil Lateef4, Usma Manzoor1, Ina A Bhat1, Dheera Sanadhya5, Abdul R Bhat6, Altaf U Ramzan6, Fozia Mohammad1, Iqra Anwar1. 1. Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, 190011, India. 2. Immunology & Molecular Medicine, SKIMS, Srinagar, J&K, 190011, India. 3. Department of Pathology, SKIMS, Srinagar, J&K, 190011, India. 4. SRM University, Chennai, 603203, India. 5. Department of Biochemistry, School of life Sciences, Jaipur National University, 302004, India. 6. Department of Neurosurgery, SKIMS, Srinagar, J&K, 190011, India.
Abstract
AIM: The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. MATERIALS & METHODS: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation by DNA sequencing and methylation-specific PCR, respectively. RESULTS: Mutations found in IDH1/2 genes totaled 63.4% (N = 40) wherein IDH1 mutations were significantly associated with oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002). IDH1 mutants presented more, 60.5% in MGMT promoter-methylated cases (p = 0.03). IDH1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p = 0.01). Multivariate analysis confirmed better survival in MGMT methylation carriers (hazard ratio [HR]: 0.59; p = 0.031). Combination of both biomarkers showed better prognosis on temozolomide (p < 0.05). CONCLUSION: IDH1/2 mutations proved independent prognostic factors in glioma and associated with MGMT methylation for better survival.
AIM: The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. MATERIALS & METHODS: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation by DNA sequencing and methylation-specific PCR, respectively. RESULTS: Mutations found in IDH1/2 genes totaled 63.4% (N = 40) wherein IDH1 mutations were significantly associated with oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002). IDH1 mutants presented more, 60.5% in MGMT promoter-methylated cases (p = 0.03). IDH1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p = 0.01). Multivariate analysis confirmed better survival in MGMT methylation carriers (hazard ratio [HR]: 0.59; p = 0.031). Combination of both biomarkers showed better prognosis on temozolomide (p < 0.05). CONCLUSION: IDH1/2 mutations proved independent prognostic factors in glioma and associated with MGMT methylation for better survival.
Authors: M Esteller; M Toyota; M Sanchez-Cespedes; G Capella; M A Peinado; D N Watkins; J P Issa; D Sidransky; S B Baylin; J G Herman Journal: Cancer Res Date: 2000-05-01 Impact factor: 12.701
Authors: M Belanich; M Pastor; T Randall; D Guerra; J Kibitel; L Alas; B Li; M Citron; P Wasserman; A White; H Eyre; K Jaeckle; S Schulman; D Rector; M Prados; S Coons; W Shapiro; D Yarosh Journal: Cancer Res Date: 1996-02-15 Impact factor: 12.701
Authors: Martin J van den Bent; Hendrikus J Dubbink; Yannick Marie; Alba A Brandes; Martin J B Taphoorn; Pieter Wesseling; Marc Frenay; Cees C Tijssen; Denis Lacombe; Ahmed Idbaih; Ronald van Marion; Johan M Kros; Winand N M Dinjens; Thierry Gorlia; Marc Sanson Journal: Clin Cancer Res Date: 2010-02-16 Impact factor: 13.801
Authors: Lilia Dimitrov; Christopher S Hong; Chunzhang Yang; Zhengping Zhuang; John D Heiss Journal: Int J Med Sci Date: 2015-01-20 Impact factor: 3.738
Authors: Brigitta G Baumert; Monika E Hegi; Martin J van den Bent; Andreas von Deimling; Thierry Gorlia; Khê Hoang-Xuan; Alba A Brandes; Guy Kantor; Martin J B Taphoorn; Mohamed Ben Hassel; Christian Hartmann; Gail Ryan; David Capper; Johan M Kros; Sebastian Kurscheid; Wolfgang Wick; Roelien Enting; Michele Reni; Brian Thiessen; Frederic Dhermain; Jacoline E Bromberg; Loic Feuvret; Jaap C Reijneveld; Olivier Chinot; Johanna M M Gijtenbeek; John P Rossiter; Nicolas Dif; Carmen Balana; Jose Bravo-Marques; Paul M Clement; Christine Marosi; Tzahala Tzuk-Shina; Robert A Nordal; Jeremy Rees; Denis Lacombe; Warren P Mason; Roger Stupp Journal: Lancet Oncol Date: 2016-09-27 Impact factor: 54.433